150 related articles for article (PubMed ID: 34653593)
1. One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma.
Louis C; Coulouarn C
J Hepatol; 2022 Jan; 76(1):8-10. PubMed ID: 34653593
[No Abstract] [Full Text] [Related]
2. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
Chen Q; Wang H; Li Z; Li F; Liang L; Zou Y; Shen H; Li J; Xia Y; Cheng Z; Yang T; Wang K; Shen F
J Hepatol; 2022 Jan; 76(1):135-147. PubMed ID: 34509526
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
Shen DY; Zhang W; Zeng X; Liu CQ
Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562
[TBL] [Abstract][Full Text] [Related]
4. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells.
Zhang KS; Zhou Q; Wang YF; Liang LJ
Oncol Rep; 2013 Sep; 30(3):1430-8. PubMed ID: 23799613
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin Is a Novel Target in YES-associated Protein-driven Cholangiocarcinoma.
Lozano A; Lujambio A
Gastroenterology; 2022 Aug; 163(2):374-376. PubMed ID: 35661722
[No Abstract] [Full Text] [Related]
7. The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma.
Yang H; Zhao Y; Song W; Fan G
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127627. PubMed ID: 37884243
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway.
Shi Z; Zhou L; Zhou Y; Jia X; Yu X; An X; Han Y
BMB Rep; 2022 Jun; 55(6):299-304. PubMed ID: 35651328
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Lim K; Han C; Xu L; Isse K; Demetris AJ; Wu T
Cancer Res; 2008 Jan; 68(2):553-60. PubMed ID: 18199552
[TBL] [Abstract][Full Text] [Related]
10. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.
Loilome W; Bungkanjana P; Techasen A; Namwat N; Yongvanit P; Puapairoj A; Khuntikeo N; Riggins GJ
Tumour Biol; 2014 Jun; 35(6):5357-67. PubMed ID: 24549785
[TBL] [Abstract][Full Text] [Related]
11. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.
Boulter L; Guest RV; Kendall TJ; Wilson DH; Wojtacha D; Robson AJ; Ridgway RA; Samuel K; Van Rooijen N; Barry ST; Wigmore SJ; Sansom OJ; Forbes SJ
J Clin Invest; 2015 Mar; 125(3):1269-85. PubMed ID: 25689248
[TBL] [Abstract][Full Text] [Related]
12. Moving upstream in the war on WNTs.
Virshup DM
J Clin Invest; 2015 Mar; 125(3):975-7. PubMed ID: 25689251
[TBL] [Abstract][Full Text] [Related]
13. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
[TBL] [Abstract][Full Text] [Related]
14. RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma.
Chang J; Zhang Y; Zhou T; Qiao Q; Shan J; Chen Y; Jiang W; Wang Y; Liu S; Wang Y; Yu Y; Li C; Li X
J Exp Clin Cancer Res; 2024 Apr; 43(1):104. PubMed ID: 38576051
[TBL] [Abstract][Full Text] [Related]
15. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
16. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity.
Lozano E; Sanchon-Sanchez P; Morente-Carrasco A; Chinchilla-Tábora LM; Mauriz JL; Fernández-Palanca P; Marin JJG; Macias RIR
Cells; 2023 Apr; 12(8):. PubMed ID: 37190050
[TBL] [Abstract][Full Text] [Related]
17. Biliary tract: Therapeutic strategies for cholangiocarcinoma-wishing on WNT inhibitors?
Ray K
Nat Rev Gastroenterol Hepatol; 2015 Apr; 12(4):187. PubMed ID: 25752712
[No Abstract] [Full Text] [Related]
18. Expression of transforming growth factor betas and their signaling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma.
Lee KT; Liu TS
World J Surg; 2003 Oct; 27(10):1143-8. PubMed ID: 12917766
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma.
Huang GL; Luo Q; Rui G; Zhang W; Zhang QY; Chen QX; Shen DY
Mol Cell Biol; 2013 Sep; 33(17):3416-25. PubMed ID: 23798555
[TBL] [Abstract][Full Text] [Related]
20. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
